APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha 1 Antitrypsin Deficiency Treatment

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Selected research

Market Structure

Global Alpha 1 Antitrypsin Deficiency Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025193 pages

Choose your research edition.

Industry ResearchAlpha 1 Antitrypsin Deficiency Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha 1 Antitrypsin Deficiency Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Alpha 1 Antitrypsin Deficiency Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

Report Includes

Read the full market overview

This report provides an overview of the global Alpha 1 Antitrypsin Deficiency Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alpha 1 Antitrypsin Deficiency Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alpha 1 Antitrypsin Deficiency Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Alpha 1 Antitrypsin Deficiency Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Alpha 1 Antitrypsin Deficiency Treatment Segment by Company

Pfizer

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Teva Pharmaceutical Industries

Takeda

Baxter

Grifols

CSL Behring

Kamada Ltd

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

Alpha 1 Antitrypsin Deficiency Treatment Segment by Indication

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Other

Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users

COPD

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Alpha 1 Antitrypsin Deficiency Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Alpha 1 Antitrypsin Deficiency Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha 1 Antitrypsin Deficiency Treatment industry.

Chapter 3: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Alpha 1 Antitrypsin Deficiency Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Augmentation Therapy Table 3. Key Players of Cystic Fibrosis(CF) Table 4. Key Players of Non-CF Bronchiectasis(NCFB) Table 3. Key Players of Diabetes Table 4. Key Players of Other Table 5. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of COPD Table 7. Key Players of Cystic Fibrosis(CF) Table 8. Key Players of Non-CF Bronchiectasis(NCFB) Table 9. Key Players of Diabetes Table 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2021-2026) Table 13. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2027-2032) Table 15. Alpha 1 Antitrypsin Deficiency Treatment Industry Trends Table 16. Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers Table 17. Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges Table 18. Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints Table 19. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Company (2021-2026) Table 21. Global Alpha 1 Antitrypsin Deficiency Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Key Company Head Office and Area Served Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Company, Product Type & Application Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2021-2026) Table 36. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2027-2032) Table 37. Pfizer Company Information Table 38. Pfizer Business Overview Table 39. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 41. Pfizer Recent Development Table 42. GlaxoSmithKline Company Information Table 43. GlaxoSmithKline Business Overview Table 44. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 46. GlaxoSmithKline Recent Development Table 47. AstraZeneca Company Information Table 48. AstraZeneca Business Overview Table 49. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 51. AstraZeneca Recent Development Table 52. Boehringer Ingelheim Company Information Table 53. Boehringer Ingelheim Business Overview Table 54. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 56. Boehringer Ingelheim Recent Development Table 57. Teva Pharmaceutical Industries Company Information Table 58. Teva Pharmaceutical Industries Business Overview Table 59. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 61. Teva Pharmaceutical Industries Recent Development Table 62. Takeda Company Information Table 63. Takeda Business Overview Table 64. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 66. Takeda Recent Development Table 67. Baxter Company Information Table 68. Baxter Business Overview Table 69. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 71. Baxter Recent Development Table 72. Grifols Company Information Table 73. Grifols Business Overview Table 74. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 76. Grifols Recent Development Table 77. CSL Behring Company Information Table 78. CSL Behring Business Overview Table 79. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 81. CSL Behring Recent Development Table 82. Kamada Ltd Company Information Table 83. Kamada Ltd Business Overview Table 84. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 86. Kamada Ltd Recent Development Table 87. Chiesi Pharmaceuticals Company Information Table 88. Chiesi Pharmaceuticals Business Overview Table 89. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 91. Chiesi Pharmaceuticals Recent Development Table 92. Kedrion Group Company Information Table 93. Kedrion Group Business Overview Table 94. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 96. Kedrion Group Recent Development Table 97. Vertex Pharmaceuticals Company Information Table 98. Vertex Pharmaceuticals Business Overview Table 99. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 101. Vertex Pharmaceuticals Recent Development Table 102. ProMetic Life Sciences Company Information Table 103. ProMetic Life Sciences Business Overview Table 104. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 106. ProMetic Life Sciences Recent Development Table 107. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026) & (US$ Million) Table 108. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032) & (US$ Million) Table 109. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026) & (US$ Million) Table 110. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032) & (US$ Million) Table 111. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) Table 113. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032) Table 114. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026) & (US$ Million) Table 115. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032) & (US$ Million) Table 116. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026) & (US$ Million) Table 117. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032) & (US$ Million) Table 118. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) Table 120. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032) Table 121. China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026) & (US$ Million) Table 122. China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032) & (US$ Million) Table 123. China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026) & (US$ Million) Table 124. China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032) & (US$ Million) Table 125. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026) & (US$ Million) Table 126. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032) & (US$ Million) Table 127. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026) & (US$ Million) Table 128. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032) & (US$ Million) Table 129. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) Table 131. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032) Table 132. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026) & (US$ Million) Table 133. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032) & (US$ Million) Table 134. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026) & (US$ Million) Table 135. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032) & (US$ Million) Table 136. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026) Table 138. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Product Image Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type: 2025 VS 2032 Figure 4. Augmentation Therapy Image Figure 5. Cystic Fibrosis(CF) Image Figure 6. Non-CF Bronchiectasis(NCFB) Image Figure 7. Diabetes Image Figure 8. Other Image Figure 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application: 2025 VS 2032 Figure 11. COPD Image Figure 12. Cystic Fibrosis(CF) Image Figure 13. Non-CF Bronchiectasis(NCFB) Image Figure 14. Diabetes Image Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Players in 2025 Figure 20. Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2032) Figure 24. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2021-2032) Figure 26. North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 27. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032) Figure 28. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032) Figure 29. North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 30. United States Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 31. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 32. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 33. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 34. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032) Figure 35. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032) Figure 36. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 37. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 38. France Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 39. U.K. Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 40. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 41. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 43. China Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 44. China Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032) Figure 45. China Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032) Figure 46. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 47. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032) Figure 48. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032) Figure 49. Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 50. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 51. South Korea Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 54. India Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 55. Australia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032) Figure 60. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 61. South Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 65. UAE Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 66. Egypt Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 67. Chile Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
  • Other
Applications
  • COPD
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
Companies covered
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries
  • Takeda
  • Baxter
  • Grifols
  • CSL Behring
  • Kamada Ltd
  • Chiesi Pharmaceuticals
  • Kedrion Group
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Augmentation Therapy
  5. 1.2.3 Cystic Fibrosis(CF)
  6. 1.2.4 Non-CF Bronchiectasis(NCFB)
  7. 1.2.5 Diabetes
  8. 1.2.6 Other
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 COPD
  12. 1.3.3 Cystic Fibrosis(CF)
  13. 1.3.4 Non-CF Bronchiectasis(NCFB)
  14. 1.3.5 Diabetes
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
  17. 1.5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2026)
  19. 1.5.3 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
  1. 2.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
  2. 2.2 Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers
  3. 2.3 Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges
  4. 2.4 Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Key Company Head office and Area Served
  4. 3.4 Global Alpha 1 Antitrypsin Deficiency Treatment Company, Product Type & Application
  5. 3.5 Global Alpha 1 Antitrypsin Deficiency Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Alpha 1 Antitrypsin Deficiency Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Alpha 1 Antitrypsin Deficiency Treatment Tier 1, Tier 2, and Tier 3
4 Alpha 1 Antitrypsin Deficiency Treatment Market by Type
  1. 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Type (2021-2032)
5 Alpha 1 Antitrypsin Deficiency Treatment Market by Application
  1. 5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Pfizer
  2. 6.1.1 Pfizer Company Information
  3. 6.1.2 Pfizer Business Overview
  4. 6.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  6. 6.1.5 Pfizer Recent Developments
  7. 6.2 GlaxoSmithKline
  8. 6.2.1 GlaxoSmithKline Company Information
  9. 6.2.2 GlaxoSmithKline Business Overview
  10. 6.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  12. 6.2.5 GlaxoSmithKline Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Boehringer Ingelheim
  20. 6.4.1 Boehringer Ingelheim Company Information
  21. 6.4.2 Boehringer Ingelheim Business Overview
  22. 6.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  24. 6.4.5 Boehringer Ingelheim Recent Developments
  25. 6.5 Teva Pharmaceutical Industries
  26. 6.5.1 Teva Pharmaceutical Industries Company Information
  27. 6.5.2 Teva Pharmaceutical Industries Business Overview
  28. 6.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  30. 6.5.5 Teva Pharmaceutical Industries Recent Developments
  31. 6.6 Takeda
  32. 6.6.1 Takeda Company Information
  33. 6.6.2 Takeda Business Overview
  34. 6.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  36. 6.6.5 Takeda Recent Developments
  37. 6.7 Baxter
  38. 6.7.1 Baxter Company Information
  39. 6.7.2 Baxter Business Overview
  40. 6.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  42. 6.7.5 Baxter Recent Developments
  43. 6.8 Grifols
  44. 6.8.1 Grifols Company Information
  45. 6.8.2 Grifols Business Overview
  46. 6.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  48. 6.8.5 Grifols Recent Developments
  49. 6.9 CSL Behring
  50. 6.9.1 CSL Behring Company Information
  51. 6.9.2 CSL Behring Business Overview
  52. 6.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  54. 6.9.5 CSL Behring Recent Developments
  55. 6.10 Kamada Ltd
  56. 6.10.1 Kamada Ltd Company Information
  57. 6.10.2 Kamada Ltd Business Overview
  58. 6.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  60. 6.10.5 Kamada Ltd Recent Developments
  61. 6.11 Chiesi Pharmaceuticals
  62. 6.11.1 Chiesi Pharmaceuticals Company Information
  63. 6.11.2 Chiesi Pharmaceuticals Business Overview
  64. 6.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  66. 6.11.5 Chiesi Pharmaceuticals Recent Developments
  67. 6.12 Kedrion Group
  68. 6.12.1 Kedrion Group Company Information
  69. 6.12.2 Kedrion Group Business Overview
  70. 6.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  72. 6.12.5 Kedrion Group Recent Developments
  73. 6.13 Vertex Pharmaceuticals
  74. 6.13.1 Vertex Pharmaceuticals Company Information
  75. 6.13.2 Vertex Pharmaceuticals Business Overview
  76. 6.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  78. 6.13.5 Vertex Pharmaceuticals Recent Developments
  79. 6.14 ProMetic Life Sciences
  80. 6.14.1 ProMetic Life Sciences Company Information
  81. 6.14.2 ProMetic Life Sciences Business Overview
  82. 6.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  84. 6.14.5 ProMetic Life Sciences Recent Developments
7 North America
  1. 7.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  2. 7.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
  3. 7.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
  7. 7.3.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
  11. 7.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  2. 8.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
  3. 8.2.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
  7. 8.3.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
  11. 8.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  2. 9.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
  3. 9.2.1 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032)
  6. 9.3 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
  7. 9.3.1 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  2. 10.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
  3. 10.2.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
  7. 10.3.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
  11. 10.4.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst